Total Voting Rights

RNS Number : 9718D

Hikma Pharmaceuticals Plc

02 November 2020

 

Hikma Pharmaceuticals PLC

(the Company)

Total Voting Rights and Capital

LONDON, 2 November 2020 - In accordance with the UK Financial Conduct Authority's (the "FCA") DTR 5.6.1, Hikma Pharmaceuticals PLC (LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) notifies the market that, in accordance with the Disclosure Guidance and Transparency Rules ('the Rules'), we notify the market of the following:

As at 31 October 2020, the issued share capital of the Company comprised of 230,496,614 ordinary shares with voting rights. This figure excludes 12,833,433 Shares held in treasury.

The figure of 230,496,614 may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Rules.

- ENDS -

Enquiries

Hikma Pharmaceuticals PLC
Peter Speirs Company Secretary	[phone]

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit:  www.hikma.com .

 

END

 

 

TVREADFAEAEEFFA